LAS VEGAS, NV — (Marketwired) — 07/13/16 — (OTCQB: CMXC) ("Cell MedX" or the "Company"), a development stage company focused on the commercialization of therapeutic devices for patients living with diseases such as diabetes, is pleased to provide its shareholders with an update on its observational clinical trial carried out by Nutrasource Diagnostics Inc. ("NDI") as well as its research and development of the eBalance Devices.Further to the news release the Com
LAS VEGAS, NV — (Marketwired) — 03/22/16 — (OTCQB: CMXC), ("Cell MedX" or the "Company") is pleased to announce that it has engaged Nutrasource Diagnostics Inc. ("NDI") to commence clinical trials of its innovative and proprietary technology branded under the trade name eBalance. The intent of the upcoming trial is to assess and quantify eBalance–s ability to alter key metabolic pathways targeting improved blood sugar control. The trial will be conducted at se
